淫羊藿苷与葛根素的复方药对生长期大鼠峰值骨量的影响

Effects of compound medicine of icariin and puerarin on peak bone mass in growing rats

目的研究淫羊藿苷与葛根素的复方药对生长期大鼠峰值骨量(peak bone mass, PBM)的影响,并探讨其可能的机制。方法1月龄雌性SD大鼠40只,随机分为正常对照组(control, C)、淫羊藿苷组(icariin, I)、葛根素(puerarin, P)组、淫羊藿苷与葛根素的复方组(I+P),每组10只。每两周称取1次体重,每月用双能X射线骨密度仪检测全身骨密度,待用药组与对照组间全身骨密度差异有统计学意义后,处死动物并取材。分离右侧股骨、椎骨检测离体骨密度;后用AG-IS系列台式电子万能试验机检测股骨和椎骨生物力学性能;ELISA法检测骨形成指标骨钙素(osteocalcin, OC)、Ⅰ型原胶原N端前肽(propeptide of typeⅠprocollagen, PINP)和骨吸收指标抗酒石酸酸性磷酸酶5b(tartrate-resistant acid phosphatase 5b,TRACP 5b)、Ⅰ型胶原C末端肽(typeⅠcollagen C-terminal peptide, CTX-Ⅰ)的含量变化;品红-苦味酸染色(Van-Gieson,VG)后分析骨小梁相关参数的变化。结果大鼠的体重差异无统计学意义(P>0.05);服药1个月后全身骨密度无明显差异(P>0.05),服药2个月后给药组全身骨密度均高于对照组,其中复合药物组大鼠全身骨密度、股骨和椎骨骨密度、股骨最大载荷值、椎骨最大载荷值和骨小梁数目和面积、血清OC、PINP水平均增加,而骨小梁分离度、TRACP 5b、CTX-1含量降低(P<0.01)。与对照组的差异均具有统计学意义(P<0.05)。复方药物组与两味单体组在生化指标和骨组织形态上面均有显著差异(P<0.01),骨密度和生物力学则无统计学差异,但其平均值都高于单体组。结论淫羊藿苷与葛根素复方能有效提高大鼠峰值骨量。

Objective To study the effects of the compound medicine of icariin and puerarin on peak bone mass in rats during growth period, and to explore its possible mechanism. Methods Forty female Sprague-Dawley rats aged 1 month were randomly divided into normal control group(C), icariin group(I), puerarin group(P), icariin and puerarin compound groupc(I+ P), 10 in each group. The body weights were recorded once every two weeks, and the bone mineral density was measured by dual-energy X-ray absorptiometry every month. After the bone mineral density of the whole body was significantly different between the control group and drug groups, the animals were sacrificed. The right femur and vertebrae were separated to measure the bone mineral density. The biomechanical properties of the femur and vertebra were detected by AG-IS series desktop electronic universal testing machine. The bone formation index osteocalcin, PINP and bone resorption index were determined by ELISA. Changes in the contents of tartrate-resistant acid phosphatase 5b(TRACP 5b) and CTX-1;and changes in trabecular bone related parameters were recorded after magenta-picric acid staining. Results There was no significant difference in body weight between the two groups (P>0.05). There was no significant difference in whole body bone density after 1 month of treatment (P>0.05). After 2 months of treatment, the body bone density of the drug-administered group was higher than that of the control group. Whole body bone density, femur and vertebral bone density, femur maximum load value, maximum vertebrae load value and trabecular bone number and area, serum OC and PINP levels increased, while TRACP 5b and CTX-1 levels decreased(P<0.01) in drug group. The difference from the control group was statistically significant (P<0.05). There were significant differences in biochemical parameters and bone histomorphology between the compound drug group and the two-flavor monomer group (P<0.01). There was no significant difference in bone mineral density and biomechanics, but the average value was higher than that of the monomer group. Conclusion The combination of icariin and puerarin can effectively increase the peak bone mass in rats.